131-I-MIBG Expanded Access: An Open Label, Expanded Access Protocol Using I-Metaiodobenzylguanidine (131I-MIBG) Therapy in Patients With Refractory Neuroblastoma- Conditions:
Adult Studies,
Cancer - Neuroblastoma,
Medications
- Gender:
Female,
Male
Provide palliative therapy with MIBG for patients with advanced neuroblastoma Gain more information about acute and late toxicity of 131I-MIBG therapy for patients with refractory neuroblastoma ...
More
NANT 99-02: Modulation of Intensive Melphalan (L-PAM) by Buthionine Sulfoximine (BSO) with Autologous Stem Cell Support for Recurrent High-Risk Neuroblastoma (A Phase I Study)- Conditions:
Cancer - Neuroblastoma,
Medications
- Gender:
Female,
Male
1. Determine the maximum tolerated dose of melphalan when combined with buthionine sulfoximine and followed by autologous bone marrow or peripheral blood stem cell support in children with recurrent high-risk neuroblastoma. 2. Assess the toxic effects of this regimen in these patients. 3. Determine...
More
NANT 2004-03: A Phase I Study of Intravenous (Emulsion) Fenretinide in Children with Recurrent or Resistant Neuroblastoma- Conditions:
Cancer - Neuroblastoma,
Medications
- Gender:
Female,
Male
This phase I trial is studying the side effects and best dose of intravenous fenretinide in treating young patients with recurrent or resistant neuroblastoma. ...
More
NANT 2004-04: Fenretinide (4-HPR, NSC 374551) Lym-X-Sorb (LXS) Oral Powder In Patients with Recurrent or Resistant Neuroblastoma- Conditions:
Cancer - Neuroblastoma,
Medications
- Gender:
Female,
Male
The primary goals of this research study are: To determine the maximum tolerated dose of Fenretinide (4-HPR, NSC 374551) Lym-X-Sorb™LXS) Oral Powder (4-HPR/LXS oral powder) given orally, BID, for seven consecutive days every three weeks, in patients with recurrent and/or resistant neuroblastoma. To...
More
NANT 2007-02: Bevacizumab, Cyclophosphamide, and Zoledronic Acid in Treating Patients with Recurrent or Refractory High-Risk Neuroblastoma- Conditions:
Adult Studies,
Cancer - Neuroblastoma,
Medications
- Gender:
Female,
Male
This phase I trial is studying the side effects of giving bevacizumab together with cyclophosphamide and zoledronic acid in treating patients with recurrent or refractory high-risk neuroblastoma....
More
NANT 2007-03: Vorinostat With 131I-MIBG Therapy for Resistant/Relapsed Neuroblastoma: A Phase I Study- Conditions:
Adult Studies,
Cancer - Neuroblastoma,
Medications
- Gender:
Female,
Male
This phase I trial is studying the side effects and best dose of giving vorinostat together with iobenguane I 131 in treating patients with resistant or relapsed neuroblastoma....
More
NANT 2008-02: Phase I Study of Vorinostat in Combination With 13-Cis-Retinoic Acid in Patients With Refractory/Recurrent Neuroblastoma- Conditions:
Cancer - Neuroblastoma,
Medications
- Gender:
Female,
Male
This phase I trial is studying the side effects and the best dose of vorinostat when given together with isotretinoin to see how well it works in treating patients with high-risk refractory or recurrent neuroblastoma. ...
More
RELRB1: A Pilot Study of Intravenous Topotecan and Vincristine in Combination with Subconjunctival Carboplatin for Patients with a History of Bilateral Retinoblastoma and Refractory/Recurrent Intraocular Disease- Conditions:
Cancer - Retinoblastoma,
Medications
- Gender:
Female,
Male
The investigators are testing intravenous topotecan and vincristine in combination with subtenon carboplatin in the hopes of finding a drug combination that may be effective against retinoblastoma that has come back or is resistant to other treatment. ...
More
A Research Study for Children (12 and older) and Adults with Sickle Cell Disease- Zileuton- Conditions:
Adult Studies,
Asthma,
Hematology - Sickle Cell and Hemoglobin,
Medications
- Gender:
Female,
Male
We find that patients with sickle cell disease (SCD) have inflammation in their blood even when they are well, and their lung function tests suggest a tendency to have asthma. Inflammation and asthma increase the number of acute sickle events. Our laboratory research shows that both inflammation an...
More
ADVL1114: A Phase I Study of Temsirolimus (CCI-779, IND# 61010) in Combination With Intensive Re-Induction Therapy for Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkin Lymphoma- Conditions:
Cancer - Leukemia and Lymphoma
- Gender:
Female,
Male
This phase I trial studies the side effects and the best dose of temsirolimus when given together with dexamethasone, mitoxantrone hydrochloride, vincristine sulfate, and pegaspargase in treating young patients with relapsed acute lymphoblastic leukemia or non-Hodgkin lymphoma....
More
